Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Cited by (1,000)

Items 301–400 of 1,000

1. A human pluripotent stem cell-based model of SARS-CoV-2 infection reveals an ACE2-independent inflammatory activation of vascular endothelial cells through TLR4
   Zhangjing Ma, Xisheng Li, Rebecca L.Y. Fan, Yi Yang, Calvin S.H. Ng, Rainbow W. H. Lau, Randolph H.L. Wong, Kevin Kan‐Shing Ng, Chi Chiu Wang, Peng Ye et al. · 2022 · Stem Cell Reports
2. Prevalence, Clinical Manifestations, and Biochemical Data of Hypertensive versus Normotensive Symptomatic Patients with COVID-19: A Comparative Study.
   Vincenzo De Sanctis · 2020 · PubMed Central
3. Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint
   Francesco Paolo Cappuccio, Alfonso Siani · 2020 · Nutrition Metabolism and Cardiovascular Diseases
4. Use of distinct anti‐hypertensive drugs and risk for COVID‐19 among hypertensive people: A population‐based cohort study in Southern Catalonia, Spain
   Ángel Vila-Córcoles, Eva María Satué-Gracia, Olga Ochoa Gondar, Cristina Torrente‐Fraga, Fréderic Gómez-Bertomeu, Ángel Vila-Rovira, Cinta de Diego‐Cabanes, Ferran Bejarano‐Romero, Dolors Rovira‐Veciana, Josep Basora · 2020 · Journal of Clinical Hypertension
5. Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection
   Ya Liu, Haigang Zhang · 2021 · Frontiers in Medicine
6. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs
   Michele Mario Ciulla · 2020 · Hypertension Research
7. Cardiological society of India position statement on COVID-19 and heart failure
   S Harikrishnan, Padinhare Purayil Mohanan, Vijay Chopra, Ambuj Roy, G. Sanjay, Manish Bansal, R.N. Chakraborty, Sharad Chandra, S S Chattarjee, H K Chopra et al. · 2020 · Indian Heart Journal
8. Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension
   Carmine Savoia, Emanuele Arrabito, Rosa Parente, Carmine Nicoletti, Luca Madaro, Allegra Battistoni, Antonio Filippini, U. Muscha Steckelings, Rhian M. Touyz, Massimo Volpe · 2020 · Hypertension
9. COVID-19 and Cardiovascular Comorbidities
   Dirk Müller‐Wieland, Nikolaus Marx, Michael Dreher, Katharina Fritzen, Oliver Schnell · 2020 · Experimental and Clinical Endocrinology & Diabetes
10. Targeting the renin−angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges
    K. Sriram, R. Loomba, P. Insel · 2020 · Proceedings of the National Academy of Sciences of the United States of America
11. Effects of renin‐angiotensin‐aldosterone system inhibitors on disease severity and mortality in patients with COVID‐19: A meta‐analysis
    Guoyue Zhang, Yue Wu, Rui Xu, Xianzhi Du · 2020 · Journal of Medical Virology
12. Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm
    Xiang Peng, Yani Wang, Xiangwen Xi, Ying Jia, Jiangtian Tian, Bo Yu, Jinwei Tian · 2021 · Cardiovascular Drugs and Therapy
13. Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets
    J. Pedro Teixeira, Sharon Barone, Kamyar A. Zahedi, Manoocher Soleimani · 2022 · International Journal of Molecular Sciences
14. Sacubitril, valsartan and SARS-CoV-2
    Antonio Vitiello, Raffaele La Porta, Francesco Ferrara · 2020 · BMJ Evidence-Based Medicine
15. ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking
    Chidinma L. Onweni, Yu Shrike Zhang, Thomas R. Caulfield, Christopher E. Hopkins, DeLisa Fairweather, William David Freeman · 2020 · Critical Care
16. Renin-angiotensin system at the interface of COVID-19 infection
    Rukhsana Gul, Uh‐Hyun Kim, Assim Abdulaziz Alfadda · 2020 · European Journal of Pharmacology
17. Potential mechanisms of cerebrovascular diseases in COVID-19 patients
    Manxue Lou, Dezhi Yuan, Shengtao Liao, Linyan Tong, Jinfang Li · 2021 · Journal of NeuroVirology
18. Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19
    Hawraa Issa, Ali Hussein Eid, Bassam Berry, Vahideh Takhviji, Abbas Khosravi, Sarah Mantash, Rawan Nehme, Rawan Hallal, Hussein Karaki, Kawthar Dhayni et al. · 2021 · Frontiers in Medicine
19. Risk factors for mortality of adult patients with COVID-19 hospitalised in an emerging country: a cohort study
    Alfonso Martin Cueto-Manzano, María Claudia Espinel‐Bermúdez, Sandra O. Hernández‐González, Enrique Rojas Campos, Arnulfo Hernán Nava-Zavala, Clotilde Fuentes‐Orozco, Luz-Ma-Adriana Balderas-Peña, Alejandro González‐Ojeda, Laura Cortés–Sanabria, Mario Alberto Mireles-Ramírez et al. · 2021 · BMJ Open
20. COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19
    Shigeru Shibata, Kazuo Kobayashi, Masami Tanaka, Kei Asayama, Eiichiro Yamamoto, Hironori Nakagami, Satoshi Hoshide, Takuya Kishi, Chisa Matsumoto, Masaki Mogi et al. · 2022 · Hypertension Research
21. Patient characteristics and admitting vital signs associated with coronavirus disease 2019 (COVID-19)–related mortality among patients admitted with noncritical illness
    Sands, Kenneth E., Wenzel, Richard P., McLean, Laura E., Korwek, Kimberly M., Roach, Jonathon D., Miller, Karla M., Poland, Russell E., Burgess, L. Hayley, Jackson, Edmund S., Perlin, Jonathan B. · 2021 · Infection Control & Hospital Epidemiology
22. Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection
    Imran Chaudhri, Farrukh M. Koraishy, Olena Bolotova, Jeanwoo Yoo, Luis A. Marcos, Erin M. Taub, Haseena Sahib, Michelle Weisfelner Bloom, Sahar Ahmad, Hal A. Skopicki et al. · 2020 · Kidney360
23. The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID ‐19
    Zihui Xu, Zhongjing Wang, Shuo Wang, Yingchun Ye, Deng Luo, Li Wan, Ailin Yu, Lifang Sun, Solomon Hailemariam Tesfaye, Qingtao Meng et al. · 2020 · Journal of Diabetes
24. Covid-19 Effects on ARTErial StIffness and Vascular AgeiNg: CARTESIAN Study Rationale and Protocol
    Rosa María Bruno, Bart Spronck, Bernhard Hametner, Alun David Hughes, Patrick J. Lacolley, Christopher Clemens Mayer, María Lorenza Muiesan, Chakravarthi Rajkumar, Dimitrios G. Terentes-Printzios, Thomas Weber et al. · 2020 · Artery Research
25. Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review
    Yasaman Sharifi, Moloud Payab, Erfan Mohammadi‐Vajari, Seyed Morsal Mosallami Aghili, Farshad Sharifi, Neda Mehrdad, Elham Kashani, Zhaleh Shadman, Bagher A. Larijani, Mahbube Ebrahimpur · 2021 · Journal of Diabetes & Metabolic Disorders
26. The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis
    Samit Ghosal, Jagat Jyoti Mukherjee, Binayak Sinha, Kalyan Kumar Gangopadhyay · 2020 · medRxiv
27. Determining host factors contributing to disease severity in a family cluster of 29 hospitalized SARS‐CoV‐2 patients: Could genetic factors be relevant in the clinical course of COVID‐19?
    Hande İkitimur, Betül Börkü Uysal, Mahir Cengız, Barış İkitimur, Harun Uysal, Erkan Özcan, Mehmet Sami İslamoğlu, Serhat Seyhan, Hakan Yavuzer, Serap Yavuzer · 2020 · Journal of Medical Virology
28. The renin–angiotensin–aldosterone system as a link between obesity and coronavirus disease 2019 severity
    Ioannis Akoumianakis, Theodosios D. Filippatos · 2020 · Obesity Reviews
29. Clinical features and risk factors for ICU admission in COVID-19 patients with cardiovascular diseases
    Feng He, Yibo Quan, Ming Lei, Riguang Liu, Shuguang Qin, Jun Zeng, Ziwen Zhao, Na Hee Yu, Liuping Yang, Jie Cao · 2020 · Aging and Disease
30. Survival rate in hypertensive patients with COVID-19
    Amir Emami, Fatemeh Javanmardi, Ali Akbari, Javad Kojuri, Hamid Bakhtiari, Tahereh Rezaei, Abdolkhalegh Keshavarzi, Farshad Falahati · 2020 · Clinical and Experimental Hypertension
31. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis
    Kevin Bryan Lo, Ruchika Bhargav, Grace Salacup, Jerald Pelayo, Jeri Albano, Peter Andrew McCullough, Janani Rangaswami · 2020 · Expert Review of Cardiovascular Therapy
32. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19
    Philip Braude, Ben Carter, Roxanna Short, Arturo Vilches‐Moraga, Alessia Verduri, Lyndsay E. Pearce, Angeline Price, Terence J. Quinn, Michael Stechman, Jemima Collins et al. · 2020 · IJC Heart & Vasculature
33. Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress
    Md. Jamal Hossain, S. M. Abdur Rahman · 2020 · Expert Review of Anti-infective Therapy
34. Cardiovascular aspects of COVID-19
    David J. Kurz, Franz Robert Eberli · 2020 · Swiss Medical Weekly
35. Single-Cell Transcriptome Analysis Decipher New Potential Regulation Mechanism of ACE2 and NPs Signaling Among Heart Failure Patients Infected With SARS-CoV-2
    Mengqiu Ma, Yanhua Xu, Yang Su, Sang‐Bing Ong, Xingdong Hu, Min Chai, Maojun Zhao, Hong Li, Xiaojuan Fan, Yingjie Chen et al. · 2021 · Frontiers in Cardiovascular Medicine
36. Heart failure outcomes and Covid-19
    Eberhard Standl, Oliver Schnell · 2021 · Diabetes Research and Clinical Practice
37. Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19
    Rhian M. Touyz, Marcus O.E. Boyd, Tomasz Jan Guzik, Sandosh Padmanabhan, Linsay McCallum, Christian Delles, Patrick Barry Mark, John R. Petrie, Francisco J. O. Rios, Augusto C. I. Montezano et al. · 2021 · CJC Open
38. Acute and Chronic Effects of COVID-19 on the Cardiovascular System
    Víctor Arévalos, Luis Ortega‐Paz, Juan José Rodríguez-Arias, Margarita Calvo-López, Leticia Camino Castrillo Golvano, Anthony Salazar-Rodríguez, Marta Sabaté-Tormos, Francesco Spione, Manel Sabaté, Salvatore Brugaletta · 2021 · Journal of Cardiovascular Development and Disease
39. COVID-19 – Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?
    Ruth H. Arnold · 2020 · Heart Lung and Circulation
40. Cardio‐Oncology in the Era of the COVID‐19 Pandemic and Beyond
    Daniel Addison, Courtney M. Campbell, Avirup Guha, Arjun Kumar Ghosh, Susan Faye Dent, Hani M. Jneid · 2020 · Journal of the American Heart Association
41. Mortality and Pre‐Hospitalization Use of Renin‐Angiotensin System Inhibitors in Patients with Hypertension and Coronavirus Disease 2019 (COVID‐19)
    Chen Chen, Feng Wang, Peng Chen, Jiangang Jiang, Guanglin Cui, Ning Zhou, Francesco Moroni, Javid J. Moslehi, Enrico Ammirati, Dao Wen Wang · 2020 · Journal of the American Heart Association
42. Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia
    Matthew Geriak, Fadi A. Haddad, Ravina Kullar, Kristina L. Greenwood, MacKenzie Habib, Cole Habib, David C. Willms, George Sakoulas · 2021 · Infectious Diseases and Therapy
43. Effects of Renin–Angiotensin–Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial
    Farhad Najmeddin, Maedeh Solhjoo, Haleh Ashraf, Mohammadreza Salehi, Fatemeh Rasooli, Morteza Ghoghaei, Abbas Soleimani, Maryam Bahreini · 2021 · American Journal of Hypertension
44. Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
    Dongling Liu, Xiang Zeng, Zufeng Ding, Fenghua Lv, Jawahar L. Mehta, Xianwei Wang · 2021 · Frontiers in Pharmacology
45. COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
    Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu · 2021 · Frontiers in Endocrinology
46. COVID-19 and the Renin Angiotensin System: Implications for the Older Adults
    Gülistan Bahat · 2020 · The journal of nutrition health & aging
47. COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?
    Hrvoje Jakovac · 2020 · American Journal of Physiology-Heart and Circulatory Physiology
48. COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system
    César Caraballo, Megan McCullough, Michael A. Fuery, Fouad K. Chouairi, Craig Keating, Neal G. Ravindra, Paul Elliott Miller, Maricar F. Malinis, Nitu Kashyap, Allen Hsiao et al. · 2020 · PLoS ONE
49. Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
    Michael M. Pan, Alexi L. Vasbinder, Elizabeth L. Anderson, Toniemarie Catalan, Husam R. Shadid, Hanna P. Berlin, Kishan J. Padalia, Patrick O’Hayer, Chelsea Meloche, Tariq U. Azam et al. · 2021 · Journal of the American Heart Association
50. Managing hypertension during the COVID-19 pandemic
    Sunil Kumar Nadar, Muzahir Hassan Tayebjee, Michael Stowasser, James Brian Byrd · 2020 · Journal of Human Hypertension
51. Coronavirus disease 2019 ( COVID ‐19) and obesity. Impact of obesity and its main comorbidities in the evolution of the disease
    Isabel María Cornejo-Pareja, Ana María Gómez‐Pérez, José Carlos Fernández‐García, Rebeca Barahona San Millan, Alexandre Aguilera Luque, Ana de Hollanda, Amanda Jiménez, Susana Jiménez‐Múrcia, Lucero Munguía, Emilio Ortega et al. · 2020 · European Eating Disorders Review
52. Cardiovascular manifestations of COVID-19
    Yash Paul Sharma, Sourabh Agstam, Ashutosh Yadav, Anunay Gupta, Ankur Gupta · 2021 · The Indian Journal of Medical Research
53. Intravenous calcitriol administration regulates the renin-angiotensin system and attenuates acute lung injury in obese mice complicated with polymicrobial sepsis
    Chiu‐Li Yeh, Jin‐Ming Wu, Li-Han Su, Po‐Jen Yang, Po‐Chu Lee, Kuan-Yuan Chen, Sung‐Ling Yeh, Ming‐Tsan Lin · 2021 · Biomedicine & Pharmacotherapy
54. Consecuencias de la COVID-19 sobre las personas con diabetes
    Virginia Bellido, Antonio Pérez · 2020 · Endocrinología Diabetes y Nutrición
55. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19
    Muhammad Usman, Tariq Jamal Siddiqi, Muhammad Shahzeb Khan, Areeba Ahmed, Syed Saad Ali, Erin D. Michos, Michael E. Hall, Richard A. Krasuski, Stephen John Greene, Javed Butler et al. · 2020 · The American Journal of Cardiology
56. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective
    Alaa Alnefaie, Sarah M. Albogami · 2020 · Saudi Pharmaceutical Journal
57. The impact of COVID-19 on health status of home-dwelling elderly patients with dementia in East Lombardy, Italy: results from COVIDEM network
    Salvatore Caratozzolo, Alberto Zucchelli, Marinella Turla, Maria Sofia Cotelli, Sara Fascendini, Mara Zanni, Angelo Bianchetti, Matteo Peli Psy, Renzo Rozzini, Stefano Boffelli et al. · 2020 · Aging Clinical and Experimental Research
58. The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy
    Antonio Desai, Giuseppe Voza, Silvia Paiardi, Francesca Ilaria Teofilo, Giuseppe Caltagirone, Marta Ripoll Pons, Monia Aloise, Maria Kogan, Tobia Tommasini, Victor Savevski et al. · 2020 · International Journal of Cardiology
59. Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms
    Baohui Xu, Gang Li, Jia Guo, Toru Ikezoe, Karthikeshwar Kasirajan, Sihai Zhao, Ronald L. Dalman · 2021 · Journal of Vascular Surgery
60. Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions
    Yujiro Matsuishi, Bryan James Mathis, Nobutake Shimojo, Jesmin Subrina, Nobuko Okubo, Yoshiaki Inoue · 2021 · Biomedicines
61. SARS‐CoV‐2 and hypertension
    Briyanth Ravichandran, Daniela G. Grimm, Marcus Krüger, Sascha Kopp, Manfred Infanger, Markus Wehland · 2021 · Physiological Reports
62. Influence of stress induced by the first announced state of emergency due to coronavirus disease 2019 on outpatient blood pressure management in Japan
    Kazuo Kobayashi, Keiichi Chin, Shinichi Umezawa, Shun Ito, Hareaki Yamamoto, Shiro Nakano, Nobukazu Takada, Nobuo Hatori, Kouichi Tamura · 2021 · Hypertension Research
63. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
    Mostafa Akbarzadeh-Khiavi, Mitra Torabi, Leila Rahbarnia, Azam Safary · 2021 · Infection
64. Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids
    Rahmani, Waleed, Chung, Hyunjae, Sinha, Sarthak, Bui-Marinos, Maxwell P., Arora, Rohit, Jaffer, Arzina, Corcoran, Jennifer A., Biernaskie, Jeff, Chun, Justin · 2022 · iScience
65. Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019
    Jordan Swiderski, Laura Kate Gadanec, Vasso Apostolopoulos, Graham J. Moore, Konstantinos Kelaidonis, John Matsoukas, Anthony Zulli · 2023 · Biomolecules
66. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
    Jishou Zhang, Menglong Wang, Wen Ding, Jun Wan · 2020 · Life Sciences
67. Characteristics and Outcomes of a Sample of Patients With COVID-19 Identified Through Social Media in Wuhan, China: Observational Study
    Dong Liu, Yuyan Wang, Juan Wang, Jue Liu, Yongjie Yue, Wenjun Liu, Fuhai Zhang, Ziping Wang · 2020 · Journal of Medical Internet Research
68. Is Spironolactone the Preferred Renin–Angiotensin–Aldosterone Inhibitor for Protection Against COVID-19?
    Christopher Stuart Wilcox, Bertram Pitt · 2020 · Journal of Cardiovascular Pharmacology
69. Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients
    Hui Liu, Jing Chen, Qin Yang, Fang Lei, Changjiang Zhang, Juan‐Juan Qin, Ze Chen, Lihua Zhu, Xiaohui Song, Liangjie Bai et al. · 2021 · Med
70. The influence of pre-existing hypertension on coronavirus disease 2019 patients
    Zhi-Yao Wei, Rui Qiao, Jian Chen, Ji Huang, Hui Ming Wu, Wen-Jun Wang, Hua Yu, Jing Xu, Chao Wang, Chonghuai Gu et al. · 2021 · Epidemiology and Infection
71. SARS-CoV-2 Research Using Human Pluripotent Stem Cells and Organoids
    Sayaka Deguchi, Ángel Serrano‐Aroca, Murtaza M. Tambuwala, Bruce D. Uhal, Adam Brufsky, Kazuo Takayama · 2021 · Stem Cells Translational Medicine
72. Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein
    Lingbing Zhang, Yandan Zhang, Xia Qin, Xuejun Jiang, Jun Zhang, Lejiao Mao, Ziqi Jiang, Yu Liang Jiang, Gang Liu, Jingfu Qiu et al. · 2022 · Critical Care
73. Eco-friendly spectrophotometric evaluation of triple-combination therapies in the treatment strategy of patients suffering from hypertension during coronavirus pandemic – Spectralprint recognition study
    Sara El-Hanboushy, Hoda M. Marzouk, Yasmin Mohammed Fayez, Mohamed Abdelkawy, Hayam Mahmoud LOTFY · 2022 · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy
74. Molecular Epidemiology of SARS-CoV-2: The Dominant Role of Arginine in Mutations and Infectivity
    Harry F. Ridgway, Charalampos Ntallis, Christos T. Chasapis, Konstantinos Kelaidonis, Minos–Timotheos Matsoukas, Panagiotis Plotas, Vasso Apostolopoulos, Graham J. Moore, Sotirios Tsiodras, Dimitrios N. Paraskevis et al. · 2023 · Viruses
75. Renin-angiotensin system inhibition in COVID-19 patients
    Antoine A.F. de Vries · 2020 · Netherlands Heart Journal
76. Association between renin–angiotensin–aldosterone system inhibitor treatment, neutrophil–lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study
    Selçuk Görmez, Erkan Ekicibaşi, Aleks Değirmencioğlu, Ashok Paudel, Refik Erdim, Hilal Kurtoğlu, Elif EROĞLU, İbrahi̇m Hali̇l Tanboğa, Sinan Dağdelen, Nevin Sarıgüzel et al. · 2020 · Journal of Human Hypertension
77. A systematic review and meta‐analysis of the use of renin‐angiotensin system drugs and COVID‐19 clinical outcomes: What is the evidence so far?
    Amanj Baker Kurdi, Nouf Abutheraa, Lina Akil, Brian Godman · 2020 · Pharmacology Research & Perspectives
78. Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis
    Hyun Woo Lee, Chang‐Hwan Yoon, Eun Jin Jang, Chang‐Hoon Lee · 2021 · Thorax
79. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19
    Qiao Zhang, Shi‐Jun Yue, Wenxiao Wang, Yanyan Chen, Chongbo Zhao, Yijun Song, Dan Yan, Li Zhang, Yuping Tang · 2021 · The American Journal of Chinese Medicine
80. Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline
    Edmond Y. Lau, Oscar A Negrete, William F. Bennett, Brian J. Bennion, Monica K. Borucki, Feliza A. Bourguet, Aidan Epstein, Magdalena Franco, Brooke Harmon, Stewart He et al. · 2021 · Frontiers in Molecular Biosciences
81. ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review
    Lihua Qu, Chao Chen, Tong Yin, Qian Fang, Zi-Zhan Hong, Rui Zhou, Hong‐Bin Tang, Hui‐Fen Dong · 2021 · International Journal of Molecular Sciences
82. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
    Rafael Golpe, Luis A. Pérez‐de‐Llano, David Dacal-Rivas, Héctor Guerrero-Sande, Beatriz Pombo Vide, Pablo Ventura-Valcárcel · 2020 · Medicina Clínica
83. Acute Coronary Syndrome in the COVID-19 Era—Differences and Dilemmas Compared to the Pre-COVID-19 Era
    Ratko Lasica, Lazar Djukanovic, Igor Mrdović, Lidija Savić, Arsen D. Ristić, Marija D. Zdravkovic, Dragan Vojislav Simic, Gordana Krljanać, Dejana Popović, Dejan S. Simeunović et al. · 2022 · Journal of Clinical Medicine
84. Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19
    David J. Bae, David M. Tehrani, Soniya V. Rabadia, Marlene Frost, Rushi V. Parikh, Marcella Calfon Press, Olcay Aksoy, Soban Umar, Reza Ardehali, Amir B. Rabbani et al. · 2020 · The American Journal of Cardiology
85. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19
    Zhongchao Wang, Dewei Zhang, Shengming Wang, Yanhua Jin, Jianbo Huan, Yue Wu, Cheng Xia, Zhe Li, Xingshun Qi, Zhang Duanzhen et al. · 2020 · Medical Science Monitor
86. Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis
    Mohitosh Biswas, Most. Sumaiya Khatun Kali · 2021 · Scientific Reports
87. Can C-Reactive Protein to Albumin Ratio Predict In-Hospital Death Rate Due to COVID-19 in Patients With Hypertension?
    Faysal Şaylık, Tayyar Akbulut, Şafak Kaya · 2021 · Angiology
88. Time-to-Death Longitudinal Characterization of Clinical Variables and Longitudinal Prediction of Mortality in COVID-19 Patients: A Two-Center Study
    Anne L. Chen, Zirun Zhao, Wei Hou, Adam J. Singer, Haifang Li, Timothy Q. Duong · 2021 · Frontiers in Medicine
89. Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
    Graham J. Moore, José Maria Pires, Konstantinos Kelaidonis, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, John Matsoukas · 2021 · Biomolecules
90. Molecular modeling of the interaction of ligands with ACE2–SARS-CoV-2 spike protein complex
    Meden F. Isaac-Lam · 2021 · In Silico Pharmacology
91. Long-term outcomes of COVID-19 convalescents: An 18.5-month longitudinal study in Wuhan
    Yi Guo, Hao Wang, Mingzhong Xiao, Xin Guan, Yanshou Lei, Tingyue Diao, Pinpin Long, Rui Zeng, Xuefeng Lai, Hao Cai et al. · 2022 · International Journal of Infectious Diseases
92. Progress on Physical Field‐Regulated Micro/Nanomotors for Cardiovascular and Cerebrovascular Disease Treatment
    Qing You, Xinyue Shao, Jinping Wang, Xiaoyuan Shawn Chen · 2023 · Small Methods
93. Pharmacokinetic and Pharmacodynamic Interactions between Food or Herbal Products and Oral Anticoagulants: Evidence Review, Practical Recommendations, and Knowledge Gaps
    Azita H. Talasaz, Bridget McGonagle, Mohsen Hajiqasemi, Zahra Alimohammad Ghelichkhan, Parham Sadeghipour, Sina Rashedi, Adam C. Cuker, Tara Lech, Samuel Zachary Goldhaber, Douglas L. Jennings et al. · 2024 · Seminars in Thrombosis and Hemostasis
94. A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response
    Rahul S. Loungani, Michael Rehorn, Laura Kristin Newby, Jason Neil Katz, Igor Klem, Robert John Mentz, W. Schuyler Jones, Sreekanth Vemulapalli, Anita M. Kelsey, Michael A. Blazing et al. · 2020 · American Heart Journal
95. The renin–angiotensin system – a therapeutic target in COVID-19?
    Beattie RH Sturrock, Kate M Milne, Timothy J. T. Chevassut · 2020 · Clinical Medicine
96. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service
    Jaiyong Kim, Kwang‐Il Kim, Hong Bin Kim, Jong‐Hun Kim, Jong-Hun Kim, Yong-Gab Lee, Kyeong Hyang Byeon, Hae‐Kwan Cheong, the Korean Society of Hypertension · 2020 · Journal of Korean Medical Science
97. Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19
    Ying Xuan Gue, Diana Adrienne Gorog · 2020 · European Heart Journal
98. Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients
    Priyank Shah, Jack Owens, James Franklin, Yash C. Jani, Ashish Kumar, Rajkumar Prakashbhai Doshi · 2020 · Journal of Hypertension
99. Impact of Treatment with Renin–Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19
    Martín Negreira Caamaño, Jesús Piqueras‐Flores, Jorge Martínez‐Del Rio, Patricia Nieto-Sandoval-Martín-de-la-Sierra, Daniel Águila‐Gordo, Cristina Mateo-Gómez, Daniel Salas-Bravo, Marta Rodríguez Martínez, Martín Negreira-Caamaño · 2020 · High Blood Pressure & Cardiovascular Prevention
100. Impact of renin–angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study
     Yanjun Zhong, Lishu Zhao, Guobao Wu, Chunhong Hu, Chenfang Wu, Min Xu, Haiyun Dong, Quan Zhang, Guyi Wang, Bo Yu et al. · 2020 · Journal of International Medical Research